Precision genome engineering has completely revolutionized biological research and is making groundbreaking inroads to therapies. This conference will cover rapidly advancing discoveries, tools and applications in this field, covering CRISPR-Cas systems as well as other innovative engineering approaches.
Attendees will hear from field pioneers about emerging, unpublished data to accelerate their work, as well as explore real-world developments in therapeutic and agricultural realms. In particular, there will be a heavy focus on emerging cellular therapies, and how to apply cutting-edge genetic engineering approaches to enrich the potential of this transformative treatment modality.
As a joint meeting with the Keystone Symposia on “Emerging Cellular Therapies,” all attendees will gain access to both meetings and joint sessions to promote cross-disciplinary collaboration and innovation in tools, technologies and applications for genetically engineered therapies.
Shannon Weiman earned her PhD in Biomedical Sciences from the University of California, San Diego, specializing in microbiology and immunology. Prior to joining the Keystone Symposia team, she worked as a freelance writer for leaders in academic, industry and government research, including Stanford University’s Biomedical Innovation Initiative, the University of Colorado’s Biofrontiers Program, UCSF, the FDA and the American Society for Microbiology.